Avalon GloboCare Teams up with Weill Cornell Medicine to Establish Joint Translational Research Initiative in Stem Cell Technology and Regenerative Medicine
FREEHOLD, NJ–(Marketwired – February 28, 2018) – Avalon GloboCare Corp. (OTCQB: AVCO), a leading global developer of cell-based technologies, announced today that the Company has jointly established a translational research training program with the Shahin Rafii Laboratory of the Division of Regenerative Medicine at Weill Cornell Medicine, New York. This program aims to create an innovative and stimulating ecosystem to foster and support selected clinicians and researchers from Weill Cornell and Avalon along with its major clinical partner — the Lu Daopei Medical Group and hospital network, a top-ranked private hospital in China specializing in hematology, immuno-oncology, and hematopoietic stem cell transplantation. The parties in this collaboration will participate in joint translational research and training projects related to cell-based therapeutics.
Shahin Rafii, M.D., head of the Division of Regenerative Medicine as well as Director of the Ansary Stem Cell Institute at Weill Cornell Medicine has provided a collaborative roadmap for the research training initiative, which will include studying tissue-specific vascular and stromal cell niches that augment the conversion of adult endothelial cells to hematopoietic stem/progenitor cells with enhanced transplant efficiency.
“This translational research and training program will synergize Dr. Rafii’s world-class stem cell facility at Weill Cornell Medicine and our immense clinical resources at the Lu Daopei hospital network with a common objective of stimulating and accelerating cell-based technology innovation and development, process standardization, as well as knowledge exchange in regenerative medicine,” stated David Jin, M.D., Ph.D., CEO and President of Avalon GloboCare Corp. “We are very proud to initiate this endeavor with an overarching goal of integrating premium research and clinical resources worldwide to advance breakthrough, safer, and more effective cell-based therapeutics,” added Dr. Jin.
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (OTCQB: AVCO) is a global intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high impact, transformative cell-based /technologies and their clinical applications, as well as healthcare facility management through its core platforms, namely “Avalon Cell” and “Avalon Rehab.” In addition, Avalon provides strategic advisory and outsourcing services to facilitate and enhance their clients’ growth, development, as well as competitiveness in both domestic and global healthcare markets. Avalon also engages in the management of stem cell banks and specialty clinical laboratories. Through its U.S. subsidiary, GenExosome Technologies Inc., Avalon further establishes its leading role in the fields of liquid biopsy, precision medicine and regenerative medicine.
Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of the press release.
Avalon GloboCare Corp.
4400 South Street, Suite 3100
Freehold, New Jersey 07728
Crescendo Communications, LLC
Tel: (212) 671-1020